137 related articles for article (PubMed ID: 35072591)
41. 'Benifuuki' green tea containing o-methylated catechin reduces symptoms of Japanese cedar pollinosis: a randomized, double-blind, placebo-controlled trial.
Masuda S; Maeda-Yamamoto M; Usui S; Fujisawa T
Allergol Int; 2014 Jun; 63(2):211-7. PubMed ID: 24561771
[TBL] [Abstract][Full Text] [Related]
42. The differences in the involvements of loci of promoter region and Ile50Val in interleukin-4 receptor α chain gene between atopic dermatitis and Japanese cedar pollinosis.
Tanaka T; Hitomi Y; Kambayashi Y; Hibino Y; Fukutomi Y; Shibata A; Sugimoto N; Hatta K; Eboshida A; Konoshita T; Nakamura H
Allergol Int; 2012 Mar; 61(1):57-63. PubMed ID: 21918367
[TBL] [Abstract][Full Text] [Related]
43. [IMMUNOTHERAPY：SUBLINGUAL IMMUNOTHERAPY AND ANTI-IGE THERAPY FOR JAPANESE CEDAR POLLINOSIS IN JAPAN].
Okubo K
Arerugi; 2021; 70(8):948-954. PubMed ID: 34588354
[No Abstract] [Full Text] [Related]
44. Release of IL-4 and IL-5 from human peripheral blood mononuclear cells co-cultured with Japanese cedar pollen antigen in vitro.
Kimura H; Shibata Y; Minakami H; Hashizume S; Oba H; Sakaguchi M; Otsuki K; Kato M
Cell Biol Int; 2001; 25(8):841-4. PubMed ID: 11482911
[TBL] [Abstract][Full Text] [Related]
45. [Effects of drug adherence on patient outcomes to early treatment for Japanese cedar pollinosis].
Kakutani C; Ogino S; Dake Y; Ikeda H; Enomoto T
Arerugi; 2004 Jul; 53(7):669-75. PubMed ID: 15492491
[TBL] [Abstract][Full Text] [Related]
46. Severity assessment of Japanese cedar pollinosis using the practical guideline for the management of allergic rhinitis in Japan and the allergic rhinitis and its impact on asthma guideline.
Gotoh M; Yuta A; Okano M; Ohta N; Matsubara A; Okubo K
Allergol Int; 2013 Jun; 62(2):181-9. PubMed ID: 23435559
[TBL] [Abstract][Full Text] [Related]
47. Efficacy of oral administration of a heat-killed Lactobacillus gasseri OLL2809 on patients of Japanese cedar pollinosis with high Japanese-cedar pollen-specific IgE.
Gotoh M; Sashihara T; Ikegami S; Yamaji T; Kino K; Orii N; Taketomo N; Okubo K
Biosci Biotechnol Biochem; 2009 Sep; 73(9):1971-7. PubMed ID: 19734682
[TBL] [Abstract][Full Text] [Related]
48. [Effect of posterior nasal neurectomy combined with the inferior turbinate surgery for Japanese cedar pollinosis].
Kamijo A; Kuroda Y; Hatsushika K; Nakajima M; Yamamoto T; Moriyama M; Okamoto A; Kase Y; Masuyama K
Arerugi; 2013 May; 62(5):560-5. PubMed ID: 23760201
[TBL] [Abstract][Full Text] [Related]
49. [A long-term follow-up study after discontinuation of immunotherapy for Japanese cedar pollinosis].
Okuda M
Arerugi; 2006 Jun; 55(6):655-61. PubMed ID: 16883102
[TBL] [Abstract][Full Text] [Related]
50. Successful Omalizumab Treatment of Rhinogenic Contact Point Headache Complicated by Severe Cedar Pollinosis: A Case Report.
Suzaki I; Miyoshi N; Ishima T; Hirano K; Shimane T
Cureus; 2023 Dec; 15(12):e51046. PubMed ID: 38264387
[TBL] [Abstract][Full Text] [Related]
51. Continuous 6-year follow-up study of sensitization to Japanese cedar pollen and onset in schoolchildren.
Kanazawa A; Terada T; Ozasa K; Hyo S; Araki N; Kawata R; Takenaka H
Allergol Int; 2014 Mar; 63(1):95-101. PubMed ID: 24569152
[TBL] [Abstract][Full Text] [Related]
52. Roles of omalizumab in various allergic diseases.
Okayama Y; Matsumoto H; Odajima H; Takahagi S; Hide M; Okubo K
Allergol Int; 2020 Apr; 69(2):167-177. PubMed ID: 32067933
[TBL] [Abstract][Full Text] [Related]
53. [Seasonal changes of laboratory data in patients with Japanese cedar pollinosis].
Fujiwara H; Masuda M; Kubo N; Okochi H; Shimoshikiryo K; Okamoto H; Hara K; Ogawa N; Takahashi H
Rinsho Byori; 1997 May; 45(5):487-92. PubMed ID: 9170978
[TBL] [Abstract][Full Text] [Related]
54. [A cross-sectional study of factors associated with production of Japanese cedar pollen specific IgE antibody and total IgE antibody, and symptoms of Japanese cedar pollinosis in primary school children].
Ozasa K; Takenaka H; Takagi N; Aoike A
Arerugi; 1995 Dec; 44(12):1361-8. PubMed ID: 8871290
[TBL] [Abstract][Full Text] [Related]
55. Japanese cedar pollinosis: discovery, nomenclature, and epidemiological trends.
Saito Y
Proc Jpn Acad Ser B Phys Biol Sci; 2014; 90(6):203-10. PubMed ID: 24919759
[TBL] [Abstract][Full Text] [Related]
56. Association between first airborne cedar pollen level peak and pollinosis symptom onset: a web-based survey.
Bando H; Sugiura H; Ohkusa Y; Akahane M; Sano T; Jojima N; Okabe N; Imamura T
Int J Environ Health Res; 2015; 25(1):104-13. PubMed ID: 24720339
[TBL] [Abstract][Full Text] [Related]
57. [CLINICAL EFFICACY OF SUBLINGUAL IMMUNOTHERAPY IN THE THIRD TREATED YEAR WITH JAPANESE CEDAR POLLINOSIS IN 2017].
Yuta A; Ogawa Y; Suzuki Y; Ogihara H; Ohta N; Kozaki H; Shimizu T
Arerugi; 2017; 66(9):1172-1180. PubMed ID: 29129888
[TBL] [Abstract][Full Text] [Related]
58. [Willingness to pay for Japanese cedar pollinosis: comparison between pollination and non-pollination seasons].
Kakutani C; Ogino S; Irifune M; Kikumori H; Seo R; Takeda M; Tamaki A; Baba K; Dake Y; Ikeda H; Enomoto T
Arerugi; 2004 Jun; 53(6):589-95. PubMed ID: 15247521
[TBL] [Abstract][Full Text] [Related]
59. Safety profile and immunological response of dual sublingual immunotherapy with house dust mite tablet and Japanese cedar pollen tablet.
Gotoh M; Okubo K; Yuta A; Ogawa Y; Nagakura H; Ueyama S; Ueyama T; Kawashima K; Yamamoto M; Fujieda S; Sakashita M; Sakamoto H; Iwasaki N; Mori E; Endo T; Ohta N; Kitazawa H; Okano M; Asako M; Takada M; Terada T; Inaka Y; Yonekura S; Matsuoka T; Kaneko S; Hata H; Hijikata N; Tanaka H; Masuyama K; Okamoto Y
Allergol Int; 2020 Jan; 69(1):104-110. PubMed ID: 31421989
[TBL] [Abstract][Full Text] [Related]
60. The socioeconomic burden of migraine: An evaluation of productivity losses due to migraine headaches based on a population study in Germany.
Seddik AH; Branner JC; Ostwald DA; Schramm SH; Bierbaum M; Katsarava Z
Cephalalgia; 2020 Dec; 40(14):1551-1560. PubMed ID: 32762249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
